Emergency Department Discharge of Pulmonary Embolus Patients.

Authors

W Frank Peacock
Craig I. Coleman
Deborah B. Diercks
Samuel Francis
Christopher Kabrhel
Catherine Keay
Jeffrey A. Kline
Jacob Manteuffel, Henry Ford HealthFollow
Peter Wildgoose
Jim Xiang
Adam J. Singer

Recommended Citation

Frank Peacock W, Coleman CI, Diercks D, Francis S, Kabrhel C, Keay C, Kline J, Manteuffel J, Wildgoose P, Xiang J, and Singer AJ. Emergency department discharge of pulmonary embolus patients. Acad Emerg Med 2018.

Document Type

Article

Publication Date

9-1-2018

Publication Title

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine

Abstract

BACKGROUND: Hospitalization for low-risk pulmonary embolism (PE) is common, expensive, and of questionable benefit.

OBJECTIVE: The objective was to determine if low-risk PE patients discharged from the emergency department (ED) on rivaroxaban require fewer hospital days compared to standard of care (SOC).

METHODS: Multicenter, open-label randomized trial in low-risk PE defined by Hestia criteria. Adult subjects were randomized to early ED discharge on rivaroxaban or SOC. Primary outcome was total number of initial hospital hours, plus hours of hospitalization for bleeding or venous thromboembolism (VTE), 30 days after randomization. A 90-day composite safety endpoint was defined as major bleeding, clinically relevant nonmajor bleeding, and mortality.

RESULTS: Of 114 randomized subjects, 51 were early discharge and 63 were SOC. Of 112 (98.2%) receiving at least one dose of study drug, 99 (86.8%) completed the study. Initial hospital LOS was 4.8 hours versus 33.6 hours, with a mean difference of -28.8 hours (95% confidence interval [CI] = -42.55 to -15.12 hours) for early discharge versus SOC, respectively. At 90 days, mean total hospital days (for any reason) were less for early discharge than SOC, 19.2 hours versus 43.2 hours, with a mean difference of 26.4 hours (95% CI = -46.97 to -3.34 hours). At 90 days, there were no bleeding events, recurrent VTE, or deaths. The composite safety endpoint was similar in both groups, with a difference in proportions of 0.005 (95% CI = -0.18 to 0.19). Total costs were $1,496 for early discharge and $4,234 for SOC, with a median difference of $2,496 (95% CI = -$2,999 to -$2,151).

CONCLUSIONS: Low-risk ED PE patients receiving early discharge on rivaroxaban have similar outcomes to SOC, but fewer total hospital days and lower costs over 30 days.

PubMed ID

29757489

Volume

25

Issue

9

First Page

995

Last Page

1003